The COVID-19 News Sending Newly Listed CureVac Shares Higher

CureVac N.V. CVAC shares have been on a tear ever since it debuted on Wall Street Friday.

After ending the debut session at $55.90, a staggering 250% gain from the IPO price of $16, the stock was trading higher again on Monday. 

What Happened: CureVac, a German clinical-stage biopharma working on mRNA-based therapies, is developing a vaccine against the SARS-CoV-2 virus. 

An accelerated approval of the coronavirus vaccine candidate cannot be ruled out, CureVac CEO Franz-Werner Haas reportedly said Sunday. 

"We are not ruling out accelerated approval, but this can only be achieved in close cooperation with the authorities," Reuters reported, citing a statement by Hass to the Boerse Online financial website.

CureVac is in talks with different governments, Haas said in another interview to Sueddeutsche.

When asked about potential vaccine pricing, Haas reportedly said that for the contract to be worthwhile, a price of 10-15 euros ($11.87-$17.80) per dose sounds right. 

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

What's Next: Preclinical studies showed that CureVac's vaccinate candidate was active at a low dose of 2mcg and triggered fast induction of a balanced immune responses with high levels of VNTs and T-cell responses.

The company initiated a Phase 1 study in June, with preliminary results from the study expected in the fourth quarter. The company is also aiming for a fourth-quarter start for the Phase 2b/3 study.

CVAC Price Action: At last check, CureVac shares were adding 32.43% to $74.03. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs